<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631694</url>
  </required_header>
  <id_info>
    <org_study_id>MKAEWC1</org_study_id>
    <nct_id>NCT02631694</nct_id>
  </id_info>
  <brief_title>Disruption of Memory Reconsolidating as a Treatment for Panic Disorder</brief_title>
  <official_title>Targeting Fear Memory by Disrupting the Process of Reconsolidating: A New Intervention for Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University of Amsterdam</source>
  <brief_summary>
    <textblock>
      Animal and human fear conditioning studies have repeatedly shown that administering
      propranolol before or after retrieval of a previously acquired fear results in an elimination
      of the fear expression. This approach, known as disruption of fear memory reconsolidation, is
      a promising new avenue for treating anxiety disorders. The present study aims to test its
      efficacy in patients with panic disorder.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of participants diagnosed with panic disorder assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth addition (DSM-IV) Axis I Disorders</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in score on the Panic Disorder Severity Scale (PDSS-SR)</measure>
    <time_frame>Baseline, 7 days, 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide challenge using a visual analogue scale ranging from 0-100 mm</measure>
    <time_frame>3 months</time_frame>
    <description>Participants are asked to rate on a visual analogue scale ranging from 0-100 mm the degree to which they are willing to inhale carbon dioxide again if this were requested. Secondly, participants will indeed be requested to perform the challenge a second time and rate on the visual analogue scale how anxious it made them feel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Panic Appraisal Inventory (PAI)</measure>
    <time_frame>Baseline, 7 days, 3 months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Mobility Inventory (MI)</measure>
    <time_frame>Baseline, 7 days, 3 months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Body Sensations Questionnaire (BSQ)</measure>
    <time_frame>Baseline, 7 days, 3 months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Agoraphobic Cognitions Questionnaire (ACQ)</measure>
    <time_frame>Baseline, 7 days, 3 months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of participants diagnosed with panic disorder assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Panic Disorder Severity Scale (PDSS-SR)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Score on the Anxiety Sensitivity Index (ASI)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>Fear reactivation with propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fear reactivation with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No fear reactivation with propranolol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Intake of propranolol pill (40 milligram)</description>
    <arm_group_label>Fear reactivation with propranolol</arm_group_label>
    <arm_group_label>No fear reactivation with propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intake of placebo pill (40 milligram)</description>
    <arm_group_label>Fear reactivation with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbon dioxide</intervention_name>
    <description>Inhalation of 35% carbon dioxide</description>
    <arm_group_label>Fear reactivation with propranolol</arm_group_label>
    <arm_group_label>Fear reactivation with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compressed air</intervention_name>
    <description>Inhalation of air</description>
    <arm_group_label>No fear reactivation with propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a primary diagnosis of panic disorder according to DSM-V

          -  written approval of an independent physician for participation

        Exclusion Criteria:

          -  other relevant treatment for panic disorder at the time of study - e.g., Cognitive
             Behavioral Therapy (CBT)

          -  diagnosis of depression

          -  diagnosis of psychosis

          -  use of psychotropic medication

          -  history of pulmonary diseases

          -  metabolic acidosis

          -  history of cardiovascular diseases

          -  heart problems among first-degree relatives

          -  heart rate (HR) &lt; 60

          -  blood pressure (BP) &lt; 90-60 or BP &gt; 170-100

          -  history of black-outs or fainting

          -  diabetes

          -  liver or kidney diseases

          -  hyperactive production of thyroid hormones

          -  epilepsy

          -  any medication contra-indicative of the use of propranolol

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merel Kindt, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnold A.P. van Emmerik, PhD</last_name>
    <phone>0031205258604</phone>
    <email>A.A.P.vanEmmerik@uva.nl</email>
  </overall_contact>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University of Amsterdam</investigator_affiliation>
    <investigator_full_name>Mrs. M. Kindt</investigator_full_name>
    <investigator_title>Professor of Experimental and Clinical Psychology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

